Organon & Co. cash flow to debt ratio of 7.95% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Organon & Co.'s free cash flow has decreased -8.50% from $588.00M last year to $538.00M, signaling decreasing performance

Organon & Co.'s debt to equity ratio is 9.49, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Organon & Co.'s debt has decreased relative to shareholder equity from 19.14 last year to 9.49 today, signaling strengthened financials

Organon & Co. has a net debt to EBITDA ratio of 6.41x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Organon & Co.'s interest coverage ratio of 2.41 indicates that earnings with margin can cover interest payments on company debt

Organon & Co.'s profit margin has decreased (-70.42%) in the last year from 13.49% to 3.99%, signaling decreasing performance

Organon & Co.'s short-term assets of $4.35G exceed its short-term liabilities of $2.39G

Organon & Co.'s return on assets of 1.89% is lower than the 5.00% threshold, indicating inefficient asset utilization

Organon & Co.'s return on equity of 29.87%, is higher than 15.00%, indicating good performance

Organon & Co.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Organon & Co. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Organon & Co. has positive free cash flow, indicating the company generates cash after capital expenditures

Organon & Co. has a free cash flow yield of 15.18%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Organon & Co.'s yearly earnings has decreased -78.36% since last year from $864.00M to $187.00M, signaling decreasing performance

Organon & Co.'s yearly revenue has decreased -2.92% since last year from $6.40G to $6.22G, signaling decreasing performance

ROIC 5.16% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Organon & Co.'s 3-year revenue CAGR of 0.23% is positive, indicating growing revenue over the past 3 years

Organon & Co. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Organon & Co. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Organon & Co. has insufficient data to evaluate this check.

Organon & Co. has an earnings yield of 7.00%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Organon & Co. is overvalued relative to its fair value price of 2.89 based on EBITDA multiple model

Organon & Co. has an EV/EBITDA ratio of 9.18x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Organon & Co. is undervalued relative to its fair value price of 30.48 based on Earnings Fair Value model

Organon & Co. has no meaningful EPS growth rate; PEG ratio cannot be computed.

Organon & Co. has a price-to-book ratio of 3.89x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Organon & Co. has a price-to-sales ratio of 0.57x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue